New combo therapy aims to outperform standard for tough lung cancer
NCT ID NCT06670196
Summary
This study is testing if adding a new drug called SKB264 to the standard treatment (osimertinib) works better for people with a specific type of advanced lung cancer. It will involve 420 adults who have not yet received treatment for their advanced cancer. The main goal is to see if the combination can keep the cancer from growing for a longer time compared to the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510060, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.